Our research has garnered significant attention from pain medicine and addiction professionals because they understand the importance of genetic variables in determining the most effective treatments for their patients - Brian Meshkin, CEO, Proove Bio
IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 23, 2014
Proove Biosciences, the commercial and research leader in personalized medicine, presented industry leading research and data on the association between gender and opioid misuse this past weekend at the American Academy of Pain Management’ s 25th annual Clinical Meeting. The meeting took place in Phoenix, Arizona at the
Proove Biosciences presented their proprietary study on the linkage between gender and genetic predisposition to opioid misuse risk in chronic pain patients. Proove Biosciences’ very own Dr. Derrick Holman presented the research, titled the I.M.P.L.O.R.E Study (Investigation Measuring Predictive Levels of Opioid Risk by Evaluating Genotype versus Common Screening Tools). Proove Biosciences has been presenting research and data at major industry conferences and events over the last two years.
This year’s annual meeting offers attendees and industry practitioners engaging presentations by leading researchers and experts in the field of integrative pain management. The conference aims to address the benefits of using an integrative model of care to manage pain, as well as explain how research is supporting integrative pain management techniques. Additionally, the conference will feature insight on how to assess pain using a variety of strategies, and how to create treatment plans for patients with chronic pain that incorporate lifestyle and mind-body therapies.
“Our research has garnered significant attention from pain medicine and addiction professionals because they understand the importance of genetic variables in determining the most effective treatments for their patients,” stated Brian Meshkin, President of Proove Biosciences. “The I.M.P.L.O.R.E. Study was an investigation involving 1,629 chronic pain patients who were genotyped using Proove’s proprietary Narcotic Risk Profile. This observation study will help us better understand the link between addiction, treatment, and gender. We are excited to share our findings with the professionals at the American Academy of Pain Management’s 25th annual meeting, and look forward demonstrating how our genetic testing has been helping physicians better understand the individual variables associated with pain and pain treatment.”
About Proove Biosciences
Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe genetic testing can provide such knowledge. Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.
Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).